The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human phase I/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients (pts) with CLDN6-positive advanced solid tumors.
 
Timothy Yap
Employment - MD Anderson Cancer Center
Stock and Other Ownership Interests - Seagen
Consulting or Advisory Role - 858 Therapeutics; Abbvie; Acrivon Therapeutics; Adagene; Aduro Biotech; Almac Group; Amgen; Amphista Therapeutics; Artios; Astex Pharmaceuticals; AstraZeneca; Athenahealth; Atrin Pharmaceuticals; Avenzo; Avoro Capital Advisors; Axiom Biotechnologies; Baptist Health; Bayer; BeiGene; BioCity Pharma; Bloom Burton; Blueprint Medicines; Boxer; BridGene Biosciences; Bristol-Myers Squibb; C4 Therapeutics; Calithera Biosciences; Cancer Research UK; Carrick Therapeutics; Circle Pharma; Clovis Oncology; Cybrexa Therapeutics; Daiichi Sankyo; Dark Blue Therapeutics; Debiopharm Group; Diffusion Pharmaceuticals; Duke Street Bio; EcoR1 Capital; Ellipses Pharma; EMD Serono; Entos; F-Star; FoRx Therapeutics; Genesis Therapeutics; Genmab; Gerson Lehrman Group; GlaxoSmithKline; Glenmark; Globe Life Science; Grey Wolf Therapeutics; Guidepoint Global; Gustave Roussy Cancer Center; I-Mab; IDEAYA Biosciences; Idience; Ignyta; ImmuneSensor Therapeutics; IMPAC Medical Systems; Intellisphere; Janssen; Joint scientific Committee for Phase I Trials in Hong Kong; Kyn therapeutics; Kyowa Kirin International; Lumanity; MEI Pharma; Merck; Mereo BioPharma; Merit, Inc.; Monte Rosa Therapeutics; Natera; Nested Therapeutics; Nexys Therapeutics; Nimbus Therapeutics; Novocure; Odyssey Therapeutics; OncoSec; Ono Pharmaceutical; Onxeo; Oregon Health & Science University (OHSU); PanAngium Therapeutics; Pegascy; PER; Pfizer; Piper Sandler; Pliant; Prelude Therapeutics; ProLynx; Protai Bio; Radiopharma Theranostics; Repare Therapeutics; resTORbio; Roche; Ryvu Therapeutics; SAKK; Sanofi; Schrodinger; SERVIER; Synnovation; Synthis Therapeutics; Tango Therapeutics; TCG Crossover; TD2; Terns Pharmaceuticals; Terremoto Biosciences; Tessellate Bio; Theragnostics; Thryv Therapeutics; Tolremo; Tome; Trevarx Biomedical; Varian Medical Systems; Veeva; Versant Health; Vibliome Therapeutics; Voronoi Health Analytics; Xinthera; Zai Lab; ZielBio
Research Funding - Acrivon Therapeutics (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); BMS (Inst); Boundless Bio; Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); CPRIT; Cyteir (Inst); Department of Defense; EMD Serono (Inst); Exelixis; F-Star (Inst); Forbius (Inst); Genentech (Inst); Gilead Sciences; GlaxoSmithKline (Inst); Golfers Against Cancer; Haihe Biopharma (Inst); IDEAYA Biosciences; ImmuneSensor Therapeutics (Inst); InSilico Medicine; Ionis Pharmaceuticals (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Karyopharm Therapeutics (Inst); KSQ Therapeutics (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); NIH/NCI; Novartis (Inst); Pfizer (Inst); Pliant; Prelude Therapeutics; Regeneron (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Roche; Rubius Therapeutics (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Synnovation; Tango Therapeutics; Tesaro (Inst); V Foundation; Vivace Therapeutics (Inst); Zenith Epigenetics (Inst); Zentalis
 
Alberto Hernando-Calvo
Honoraria - Slingshot insights
Consulting or Advisory Role - Karger Publishers
Research Funding - Gilead Sciences (Inst)
 
Emiliano Calvo
Employment - HM Hospitales; START
Leadership - BeiGene; European Organisation for Research and Treatment of Cancer (EORTC); Merus NV; Novartis; PharmaMar; Sanofi; START
Stock and Other Ownership Interests - Oncoart Associated; START
Honoraria - HM Hospitales
Consulting or Advisory Role - Adcendo; Amunix; Anaveon; AstraZeneca/MedImmune; Bristol-Myers Squibb; Chugai Pharma; Diaccurate; Elevation Oncology; Ellipses Pharma; Genmab; Janssen-Cilag; MonTa Biosciences; MSD Oncology; Nanobiotix; Nouscom; Novartis; OncoDNA; PharmaMar; Roche/Genentech; Servier; Syneos Health; T-Knife; TargImmune Therapeutics
Research Funding - START
Other Relationship - CRIS Cancer Foundation; Foundation PharmaMar; Investigational Therapeutics in Oncological Sciences
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Abbvie; Affimed Therapeutics; AstraZeneca; Basilea; Bayer; BMS; Ellipses Pharma; Janssen Oncology; Merck; Roche
Speakers' Bureau - Bayer; Pierre Fabre
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ADC Therapeutics (Inst); Amgen (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); Biomea Fusion (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Crescendo Bioscience (Inst); Cullinan Oncology (Inst); E-therapeutics (Inst); Eisai (Inst); F-Star Biotechnology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Grey Wolf Therapeutics (Inst); hemavant (Inst); HiFiBiO Therapeutics (Inst); Janssen (Inst); Kinnate Biopharma (Inst); Menarini (Inst); Merck (Inst); MonTa Biosciences (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Revolution Medicines (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - BMS
 
Raul Marquez
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; MSD
 
Kyriakos Papadopoulos
Consulting or Advisory Role - AADi; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); Alnylam (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); Bristol-Myers Squibb/Celgene (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); F-star (Inst); Frontier Medicines (Inst); Genmab (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Parabilis Medicines (Inst); Pfizer (Inst); PharmaMar (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sensei Biotherapeutics (Inst); Storm Therapeutics (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
Javier García - Corbacho
Research Funding - Amgen; Artios; Astellas Pharma; AstraZeneca; Bayer; BioNTech; BMS GmbH & Co. KG; Boehringer Ingelheim; Debiopharm Group; Genmab; GlaxoSmithKline; MSD; Pfizer; Roche; Takeda; Tango Therapeutics; Verastem
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Pfizer
 
Tatiana Hernandez Guerrero
No Relationships to Disclose
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
David Tan
Stock and Other Ownership Interests - Asian Microbiome Library
Honoraria - AstraZeneca; Bayer; BioNTech SE; BMS; Daiichi Sankyo; Eisai; Foundation Medicine; GlaxoSmithKline; Merck; MSD; Roche; Zymeworks
Consulting or Advisory Role - AstraZeneca; Bayer; BMS; Daiichi Sankyo; Eisai; GlaxoSmithKline; Merck; MSD; Roche; Zymeworks
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Eisai; GlaxoSmithKline; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); Experimental Drug Development Centre (EDDC)/A*STAR (Inst); Karyopharm Therapeutics (Inst); MSD (Inst); National Medical Research Council/Ministry of Health Singapore; National Medical Research Council/Ministry of Health Singapore (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Daiichi Sanyo; Merck; Novartis; Roche; Zymeworks
 
Christian Ottensmeier
Stock and Other Ownership Interests - NEUVOGEN
Honoraria - Delcath Systems; Transgene
Consulting or Advisory Role - Bristol-Myers Squibb; Delcath Systems; Merck Sharp & Dohme; NEUVOGEN
Speakers' Bureau - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme; Roche
Research Funding - BioNTech (Inst); Bristol-Myers Squibb (Inst); Delcath Systems (Inst); Merck Sharp & Dohme (Inst); PsiOxus Therapeutics (Inst); Scancell (Inst); Touchlight Genetics (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - patents on modulation of T cell function
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Delcath Systems
Other Relationship - Transgene
 
Secil Koseoglu
Employment - BioNTech SE
Stock and Other Ownership Interests - BioNTech SE; Coherus Biosciences
 
Philip Chang
Employment - BioNTech
Stock and Other Ownership Interests - BioNTech
Travel, Accommodations, Expenses - BioNTech
 
Eddie Zhang
Consulting or Advisory Role - BioNTech
 
Jorge Martinez
Employment - AstraZeneca; BioNTech
Stock and Other Ownership Interests - AstraZeneca; BioNTech
Travel, Accommodations, Expenses - AstraZeneca; BioNTech
 
Christina Trück
Employment - BioNTech
Stock and Other Ownership Interests - BioNTech
 
Rita Magenheim
Employment - BioNTech
 
Ilhan Celik
Employment - BioNTech
Stock and Other Ownership Interests - BioNTech
Patents, Royalties, Other Intellectual Property - BioNTech; Merck KGaA
 
Özlem Türeci
Employment - BioNTech
Leadership - BioNTech
Stock and Other Ownership Interests - BioNTech
Research Funding - BioNTech; HI-TRON Mainz
Patents, Royalties, Other Intellectual Property - BioNTech; HI-TRON Mainz
Travel, Accommodations, Expenses - BioNTech
Other Relationship - On the Scientific Management Board (SMB) of HI-TRON; President of the Association for Cancer Immunotherapy CIMT
 
Ugur Sahin
Employment - BioNTech
Leadership - BioNTech
Stock and Other Ownership Interests - BioNTech
Research Funding - BioNTech
Patents, Royalties, Other Intellectual Property - BioNTech; Tron
Travel, Accommodations, Expenses - BioNTech
Other Relationship - Co-founder/scientific advisor at TRON; on the Scientific Management Board (SMB) of HI-TRON